SURFACTANT PROTEIN A1 AS A MOLECULAR BIOMARKER OF LUNG DAMAGE IN EXPERIMENTAL DIABETES MELLITUS.
DOI:
https://doi.org/10.11603/1811-2471.2022.v.i4.13505Keywords:
experimental diabetes mellitus, surfactant protein A1, biomarkerAbstract
SUMMARY. Diabetes mellitus occupies one of the first places in the structure of endocrine diseases and affects many organs, including the lungs. Pulmonary surfactant, mostly surfactant protein A1, plays a leading role in the pathogenesis of respiratory diseases. There is insufficient data on the use of serum surfactant protein A1 as a potential biomarker of lung damage in the scientific literature.
The aim – to evaluate the informativeness of surfactant protein A1 content in blood serum as a prognostic biomarker of lung injury in experimental diabetes mellitus.
Material and Methods. A model of diabetes mellitus, which was reproduced by intraperitoneal injection of streptozotocin by "Sigma" company (USA), diluted in 0.1 M citrate buffer with a pH of 4.5, at a rate of 60 mg/kg body weight. The control group of animals received an intraperitoneal injection with an equivalent dose of 0.1 M citrate buffer solution with a pH of 4.5. Serum levels of SP-A1 were determined by rat enzyme-linked immunosorbent assay Rat ELISA Kits (Elabscience, USA) according to the manufacturer's instructions 14, 28, 42 and 70 days after streptozotocin injection.
Results. Conducted biochemical analysis showed an increase in the levels of SP-A1 in blood serum in animals with diabetes mellitus at all stages of the experiment. In particular, serum SP-A1 levels increased by 7.9 % in 14 days, 49 % in 28 days, 69.5 % in 42 days and 91.6 % in 70 days compared to the control group of animals.
Conclusions. During the entire study period, experimental diabetes mellitus is accompanied by an increase in surfactant protein A1 levels in blood serum and can be considered as a molecular biomarker of lung damage in this pathology.
References
Sytnyk, I.M., & Khaitovych, M.V. (2015). Zastosuvannia antyoksydantiv za tsukrovoho diabetu I typu [The use of antioxidants in type I diabetes mellitus]. Farmakolohiia ta likarska toksykolohiia – Pharmacology and Drug Toxicology, 6, 3-11 [in Ukrainian].
Hloba, Ye.V., Zelinska, N.B., & Shevchenko, I.Yu. (2017). Monohennyi diabet v Ukraini: heny, fenotyp, likuvannia [MoDy in Ukraine: genes, clinical phenotypes and treatment]. Klinichna endokrynolohiia ta endokrynna khirurhiia – Clinical Endocrinology and Endocrine Surgery, 3(59), 41-49 DOI: 10.24026/1818-1384.3(59).2017.110893 [in Ukrainian].
Akasaka, H., Ohnishi, H., Narita, Y., Kameda, M., Miki, T., & Takahashi, H. (2017). The Serum Level of KL-6 Is Associated with the Risk of Insulin Resistance and New-onset Diabetes Mellitus: The Tanno-Sobetsu Study. Internal Medicine, 56, 3009-3018. DOI: 10.2169/internalmedicine. 8716-16.
Rajasurya, V., Gunasekaran, K., & Surani, S. (2020). Interstitial lung disease and diabetes. World Journal of Diabetes, 11(8), 351-357. DOI: 10.4239/wjd.v11.i8.351.
Lecube, A., Simo, R., Pallayova, M., Punjabi, N.M., Lopez-Cano, C., & Turino, C. (2017). Pulmonary function and sleep breathing: two new targets for type 2 diabetes care. Endocr. Rev., 38, 550-573. DOI: 10.1210/cr.2017-00173.
Zheng, H., Wu, J., Jin, Z., & Yan, L-J. (2017). Potential Biochemical Mechanisms of Lung Injury in Diabetes. Aging and Disease., 8(1), 7-16. DOI: 10.14336/AD.2016.0627.
Chen, X.-F., Yan, L-J, Lecube, A., & Tang, X. (2020). Editorial: Diabetes and Obesity Effects on Lung Function. Fronties in Endocrinology, 11(462), 1-2. DOI: 10.3389/fendo. 2020.00462.
Floros, I., Thorenoor, N., Tsotakos, N., & Phelps, D.S. (2021). Human surfactant protein SP-Al and SP-A2 variants differentially affect the alveolar microenvironment, surfactant structure, regulation and function of the alveolar macrophage, and animal and human survival under various conditions. Front. Immunol., 12, 2889. DOI: 10.3389/fimmu. 2021.681639.
Depicolzuane, L., Phelps, D.S., & Floros, J. (2022). Surfactant Protein-A Function: Knowledge Gained From SP-A Knockout Mice. Frontiers in Pediatrics, 9, 799693. DOI: 10.3389/fped.2021.799693.
Abdel-Razek, O., Ni, L., Yang, F., & Wang, G. (2019). Innate immunity of surfactant protein A in experimental otitis media. Innate Immun., 25, 391-400. DOI: 10.1177/ 1753425919866006.
Thorenoor, N., Kawasawa, Y.I., Gandhi, C.K., & Floros, J. (2020). Sex-specific regulation of gene expression networks by surfactant protein A (SP-A) variants in alveolar macrophages in response to klebsiella pneumoniae. Front. Immunol., 11, 1290. DOI: 10.3389/fimmu.2020.01290.
Wang, J., Zheng, P., Huang, Z., Huang, H., Xue, M., & Liao, C. (2020). Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features. BMC Pulmonary Medicine., 20, 315. DOI: 10.1186/s12890-020-01336-y.
Chiba, M., Otsuka, M., & Takahashi, H. (2018). Significance of molecular biomarkers in idiopathic pulmonary fibrosis: a mini review. Respir. Investig., 56, 384-391. DOI: 10.1016/j.resinv.2018.06.001.
King, S.D., & Chen, S.Y. (2020). Recent progress on surfactant protein A: cellular function in lung and kidney disease development. Am. J. Physiol. Cell. Physiol., 319, 316-320. DOI: 10.1152/ajpcell. 00195.2020.
Sasaki, H., Hara, Y., Taguri, M., Fujikura, Y., Murohashi, K., & Yagyu, H. (2020). Serum surfactant protein A as a surrogate biomarker of a negative heart sign among patients with interstitial lung disease. J. Med. Sci., 82, 499-508.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
